Study Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of VIR-2482 compared to placebo in preventing influenza A illness in healthy adults 18 to <65 years of age without pre-existing risk factors for serious complications from influenza infection.
- influenza A virus
Treatment Effectiveness
Effectiveness Progress
Study Objectives
6 Primary · 2 Secondary · Reporting Duration: Up to Week 84
Trial Safety
Safety Progress
Trial Design
3 Treatment Groups
VIR-2482 (Dose 1)
1 of 3
VIR-2482 (Dose 2)
1 of 3
Placebo
1 of 3
Experimental Treatment
Non-Treatment Group
3000 Total Participants · 3 Treatment Groups
Primary Treatment: VIR-2482 (Dose 1) · Has Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18 - 65 · All Participants · 2 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:About The Reviewer
Michael Gill - B. Sc.
First Published: October 10th, 2021
Last Reviewed: November 23rd, 2022
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
Who else is applying?
What state do they live in?
| Kentucky | 50.0% |
| Indiana | 50.0% |
What site did they apply to?
| Investigative Site | 100.0% |
What portion of applicants met pre-screening criteria?
| Met criteria | 100.0% |
How many prior treatments have patients received?
| 0 | 100.0% |
Why did patients apply to this trial?
- "I’m interested in participating in clinical trials"